Back to Index
Mitra K Nadim, MD
Associate Professor of Clinical Medicine
IRD 806 Off Campus Los Angeles
+1 323 226 7307


After graduating from UCLA Medical School, Dr. Nadim went to Boston for her internship and residency at the prestigious Beth Israel Hospital, which is affiliated with Harvard University’s School of Medicine. After completing a nephrology fellowship at Brigham and Women’s/Massachusetts General Hospital, Harvard University, Dr. Nadim returned to Southern California and currently serves as Assistant Professor of Clinical Medicine and Director of USC’s Hypertension Center. Dr. Nadim served as the Associate Program Director for the Nephrology Fellowship Program from 2003 – 2006.

Dr. Nadim’s major clinical and research interests concerns the diagnosis and management of resistant hypertension. she is currently one of the National Principal Investigators in the Rheos Pivitol Trial, which is a multicenter clinical trial looking at efficacy and safety of the Rheos system, an implantable baroreflex device, in subjects with resistant hypertension.


Keck School of Medicine of USC: Master Teacher Award, 2011

Golden Key National Honor Society: Member, 1988

National Kidney Foundation: Volunteer/Donor Award, 1999

University of California, Irvine: Phi Beta Kappa, 1989

Keck School of Medicine of USC: Outstanding Year II Course Award, 2013

Keck School of Medicine of USC: Outstanding Year II Teaching Award, 2011

Keck School of Medicine of USC: Outstanding Year II Teaching Award, 2004

University of California, Irvine: Excellence in Research Award, 1990

University of California, Irvine: Cum Laude, 1990

Keck School of Medicine of USC: Faculty Teaching Award, 2015

Alpha Omega Alpha: Research Fellowship Award, 1992

Keck School of Medicine of USC: Outstanding Year II Course Award, 2008

National Institutes of Health: National Research Service Award, 1999

Keck School of Medicine of USC: Medical Faculty Women's Award Research Grant, 2007

Keck School of Medicine of USC: Outstanding Year II Teaching Award, 2007

Rheos Pivitol Trial : National Principal Investigator, 2008

Keck School of Medicine: Faculty Teaching Award, 2012


Wachter R, Halbach M, Bakris GL, Bisognano JD, Haller H, Beige J, Kroon AA, Nadim MK, Lovett EG, Schafer JE, de Leeuw PW. An exploratory propensity score matched comparison of second-generation and first-generation baroreflex activation therapy systems. J Am Soc Hypertens. 2016 Dec 16. View in: PubMed

Francoz C, Nadim MK, Durand F. Kidney biomarkers in cirrhosis. J Hepatol. 2016 Oct; 65(4):809-24. View in: PubMed

Durand F, Nadim MK. Management of Acute-on-Chronic Liver Failure. Semin Liver Dis. 2016 May; 36(2):141-52. View in: PubMed

Nadim MK, Durand F, Kellum JA, Levitsky J, O'Leary JG, Karvellas CJ, Bajaj JS, Davenport A, Jalan R, Angeli P, Caldwell SH, Fernández J, Francoz C, Garcia-Tsao G, Ginès P, Ison MG, Kramer DJ, Mehta RL, Moreau R, Mulligan D, Olson JC, Pomfret EA, Senzolo M, Steadman RH, Subramanian RM, Vincent JL, Genyk YS. Management of the critically ill patient with cirrhosis: A multidisciplinary perspective. J Hepatol. 2016 Mar; 64(3):717-35. View in: PubMed

Durand F, Graupera I, Ginès P, Olson JC, Nadim MK. Pathogenesis of Hepatorenal Syndrome: Implications for Therapy. Am J Kidney Dis. 2016 Feb; 67(2):318-28. View in: PubMed

Karvellas CJ, Durand F, Nadim MK. Acute Kidney Injury in Cirrhosis. Crit Care Clin. 2015 Oct; 31(4):737-50. View in: PubMed

Al-Khafaji A, Nadim MK, Kellum JA. Hepatorenal Disorders. Chest. 2015 Aug 1; 148(2):550-8. View in: PubMed

Fong MW, Shavelle D, Weaver FA, Nadim MK. Renal denervation in heart failure. Curr Hypertens Rep. 2015 Apr; 17(4):528. View in: PubMed

Ghofrani H, Weaver FA, Nadim MK. Resistant hypertension: medical management and alternative therapies. Cardiol Clin. 2015 Feb; 33(1):75-87. View in: PubMed

Nadim MK, Annanthapanyasut W, Matsuoka L, Appachu K, Boyajian M, Ji L, Sedra A, Genyk YS. Intraoperative hemodialysis during liver transplantation: A decade of experience. Liver Transpl. 2014 Jul; 20(7):756-64. View in: PubMed

Francoz C, Nadim MK, Baron A, Prié D, Antoine C, Belghiti J, Valla D, Moreau R, Durand F. Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: Validation of current recommendations. Hepatology. 2014 Apr; 59(4):1514-21. View in: PubMed

Nadim MK, Davis CL, Sung R, Kellum JA, Genyk YS. Simultaneous liver-kidney transplantation: a survey of US transplant centers. Am J Transplant. 2012 Nov; 12(11):3119-27. View in: PubMed

Nadim MK, Sung RS, Davis CL, Andreoni KA, Biggins SW, Danovitch GM, Feng S, Friedewald JJ, Hong JC, Kellum JA, Kim WR, Lake JR, Melton LB, Pomfret EA, Saab S, Genyk YS. Simultaneous liver-kidney transplantation summit: current state and future directions. Am J Transplant. 2012 Nov; 12(11):2901-8. View in: PubMed

Nadim MK, Sung RS. Living donor liver transplantation for hepatorenal syndrome: To do or not to do? That is the question. Liver Transpl. 2012 Oct; 18(10):1138-9. View in: PubMed

Nadim MK, Genyk YS, Tokin C, Fieber J, Ananthapanyasut W, Ye W, Selby R. Impact of the etiology of acute kidney injury on outcomes following liver transplantation: acute tubular necrosis versus hepatorenal syndrome. Liver Transpl. 2012 May; 18(5):539-48. View in: PubMed

Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012 Mar-Apr; 6(2):152-8. View in: PubMed

Davenport A, Ahmad J, Al-Khafaji A, Kellum JA, Genyk YS, Nadim MK. Medical management of hepatorenal syndrome. Nephrol Dial Transplant. 2012 Jan; 27(1):34-41. View in: PubMed

Nadim MK, Kellum JA, Davenport A, Wong F, Davis C, Pannu N, Tolwani A, Bellomo R, Genyk YS. Hepatorenal syndrome: the 8th international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2012; 16(1):R23. View in: PubMed

Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011 Aug 9; 58(7):765-73. View in: PubMed

Wong F, Nadim MK, Kellum JA, Salerno F, Bellomo R, Gerbes A, Angeli P, Moreau R, Davenport A, Jalan R, Ronco C, Genyk Y, Arroyo V. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut. 2011 May; 60(5):702-9. View in: PubMed

Tokin C, Almeda J, Jain S, Kim J, Henderson R, Nadim M, Sher L, Selby RR. Blood-management programs: a clinical and administrative model with program implementation strategies. Perm J. 2009; 13(1):18-28. View in: PubMed

Pannu N, Nadim MK. An overview of drug-induced acute kidney injury. Crit Care Med. 2008 Apr; 36(4 Suppl):S216-23. View in: PubMed

Campese VM, Nadim MK, Epstein M. Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective? J Am Soc Nephrol. 2005 Mar; 16 Suppl 1:S11-7. View in: PubMed

Nadim MK, Dua R, Campese VM. Antihypertensive drugs and the kidney. Curr Cardiol Rep. 2004 Nov; 6(6):403-8. View in: PubMed

Powered bySC CTSI